DR. DAVID L SIMON, M.D., J.D.
Psychiatric in Storrs Mansfield, CT
License number
Connecticut G88443
Category
Osteopathic Medicine
Type
Addiction Medicine
License number
Connecticut 013633
Category
Osteopathic Medicine
Type
Addiction Medicine
License number
Connecticut 154633
Category
Osteopathic Medicine
Type
Addiction Medicine
License number
Connecticut 60-18004
Category
Osteopathic Medicine
Type
Addiction Medicine
License number
Connecticut MD-050916L
Category
Osteopathic Medicine
Type
Addiction Medicine
License number
Connecticut 013633
Category
Psychiatric
Type
Interventional Pain Medicine
License number
Connecticut 013633
Category
Osteopathic Medicine
Type
Pain Medicine
License number
Connecticut 013633
Category
Osteopathic Medicine
Type
Legal Medicine
License number
Connecticut 013633
Category
Psychiatric
Type
Pain Medicine
Address
Address
2
18 Floor SUITE C, Storrs Mansfield, CT 06268
PO Box 618, North Windham, CT 06250
PO Box 618, North Windham, CT 06250
Phone
(860) 356-2242
(860) 786-1192 (Fax)
(860) 786-1192 (Fax)
Organization information
See more information about DAVID L SIMON at bizstanding.comDavid L Simon M.D., J.D
18 Dog Ln, Storrs Mansfield, CT 06268
Industry:
Medical Doctor's Office, Nonclassifiable Establishments
Doing business as:
David L Simon MD
Phone:
(860) 428-7355 (Phone)
Medical Doctor:
David L. Simon (Medical Doctor)
Categories:
Anesthesiology Physicians, Pain Management Physicians & Surgeons
Professional information
Assistant Professor
Position:
graduate student at UC Davis
Location:
Storrs Mansfield, Connecticut
Industry:
Higher Education
Work:
UC Davis
-
graduate student
Sustained-Release Nalmefene Preparations And Method
US Patent:
6569866, May 27, 2003
Filed:
Aug 6, 2001
Appl. No.:
09/922873
Inventors:
David Lew Simon - Mansfield Center CT 06250
International Classification:
A61K 3144
US Classification:
514282, 514281, 514410, 424449
Abstract:
A nalmefene transdermal delivery system useful for the treatment of human patients suffering from opioid addiction.
Salts And Bases Of The 17-(Cyclopropylmethyl)-4,5 Alpha-Epoxy-6-Methylenemorphinan-3,14 Diol Molecule For Optimizing Dopamine Homeostasis During Administration Of Opioid Analgesics
US Patent:
6103258, Aug 15, 2000
Filed:
Jul 7, 1998
Appl. No.:
9/111068
Inventors:
David Lew Simon - Mansfield Center CT
International Classification:
A61P 2536, A61M 3700
US Classification:
424449
Abstract:
Methods whereby a kappa-preferring opioid blocking agent is used for optimizing dopamine homeostasis during administration of opioid analgesics and for preventing mortal respiratory depression due to drug overdose.
Pharmaceutical Compositions Containing Substrates Of Enabling Enzymes To Preferentially Deliver Drugs Away From Pbvc Or Gic Systems
US Patent:
2003003, Feb 20, 2003
Filed:
Aug 13, 2001
Appl. No.:
09/928854
Inventors:
David Simon - Mansfield Center CT, US
International Classification:
A61K009/70
US Classification:
424/449000
Abstract:
Compositions are described for linking drugs or pharmaceutical agents to substrates such that the drug or pharmaceutical agent can be rendered relatively ineffective when not exposed to an enabling enzyme contained within a compartment of a living animal or human.
Rapid Narcotic Detoxification
US Patent:
6087356, Jul 11, 2000
Filed:
May 25, 1999
Appl. No.:
9/318245
Inventors:
David Lew Simon - Mansfield Center CT
International Classification:
A61K 3155, A61K 31515, A61K 3144, A61K 3108, A61K 3105
US Classification:
514220
Abstract:
Methods for rapid detoxification of patients addicted to opioid narcotics are provided. The methods include administering nalmefene to induce acute withdrawal, and administering dextromethorphan with nalmefene or other opioid antagonists to reduce the patient's subjective feelings of residual withdrawal symptoms following detoxification. In one method of rapid detoxification, unconsciousness is induced by anesthetizing the patient with desflurane.
Compositions Of Alpha3Beta4 Receptor Antagonists And Opioid Agonist Analgesics
US Patent:
2005002, Feb 3, 2005
Filed:
May 8, 2004
Appl. No.:
10/841408
Inventors:
David Simon - Mansfield CT, US
International Classification:
A61K038/08, A61K031/485
US Classification:
514016000, 514017000, 514282000
Abstract:
Methods for use of pharmaceutical compositions containing an opioid agonist analgesic and an α3β4 nicotinic receptor antagonist effective to separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea effect of the opioid agonist.
Method For Treating Acute And Severe Diarrhea
US Patent:
5919760, Jul 6, 1999
Filed:
Jun 24, 1997
Appl. No.:
8/881478
Inventors:
David Lew Simon - Mansfield Center CT
Assignee:
Intensive Narcotic Detoxification Centers of America, LLC - Tolland CT
International Classification:
A61K 3812, A01N 4342, A01N 4346
US Classification:
514 11
Abstract:
The invention provides a method for treating acute and severe diarrhea such as that which accompanies chemotherapy and rapid narcotic detoxification. The method includes administering octreotide in an amount sufficient to alleviate the diarrhea without precipitating clinically significant bradycardia. In a preferred embodiment an anticholenergic is administered together with octreotide to further reduce the possibility of significant bradycardia. The invention also provides a method for rapidly detoxifying a patient addicted to narcotics. Acute and severe diarrhea is eliminated during detoxification by administering octreotide in according to the above-described method.
17-(Cyclopropylmethyl)-4,5Alpha-Epoxy-6-Methylenemorphinan-3,14-Diol, Hydrochloride Salt For The Purpose Of Rapid Narcotic Detoxification
US Patent:
5783583, Jul 21, 1998
Filed:
Apr 12, 1996
Appl. No.:
8/631081
Inventors:
David Lew Simon - Mansfield Center CT
International Classification:
A01N 4342, A61K 3144
US Classification:
514282
Abstract:
Methods whereby the narcotic antagonist 17-(cyclopropylmethyl)-4,5alpha-6-methylenemorphinan-3,14-diol,hydrochlori de salt and other narcotic antagonists are used for chemically precipitating a withdrawal response in human beings addicted to exogenous narcotics and who are currently using exogenous narcotics.
Compositions Of Alpha3Beta4 Receptor Antagonists And Opioid Agonist Analgesics
US Patent:
2003019, Oct 23, 2003
Filed:
Apr 22, 2002
Appl. No.:
10/127359
Inventors:
David Simon - Mansfield Center CT, US
International Classification:
A61K038/33, A61K031/7052, A61K031/485, A61K031/445, A61K031/192
US Classification:
514/012000, 514/282000, 514/317000, 514/023000, 514/161000, 514/570000
Abstract:
A pharmaceutical composition comprising an opioid agonist analgesic and an 34 nicotinic receptor antagonist effective to separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea effect of the opioid agonist.
Rapid Narcotic Detoxification
US Patent:
5922705, Jul 13, 1999
Filed:
Apr 13, 1998
Appl. No.:
9/059031
Inventors:
David Lew Simon - Mansfield Center CT
Assignee:
Intensive Narcotic Detoxification Centers of America, LLC - Tolland CT
International Classification:
A61K 3155, A61K 31515, A61K 3144, A61K 3108, A61K 3105
US Classification:
514220
Abstract:
Methods for rapid detoxification of patients addicted to opioid narcotics are provided. The methods include administering nalmefene to induce acute withdrawal, and administering dextromethorphan with nalmefene or other opioid antagonists to reduce the patient's subjective feelings of residual withdrawal symptoms following detoxification. In one method of rapid detoxification, unconsciousness is induced by anesthetizing the patient with desflurane.